Advances in tau-based drug discovery

Abstract

Introduction: Tauopathies, including Alzheimer's disease and some frontotemporal dementias, are neurodegenerative diseases characterised by pathological lesions comprised of tau protein. There is currently a significant and urgent unmet need for disease-modifying therapies for these conditions and recently attention has turned to tau as a potential target for intervention.

Areas covered: Increasing evidence has highlighted pathways associated with tau-mediated neurodegeneration as important targets for drug development. Here, the authors review recently published papers in this area and summarise the genetic and pharmacological approaches that have shown efficacy in reducing tau-associated neurodegeneration. These include the use of agents to prevent abnormal tau processing and increase tau clearance, therapies targeting the immune system, and the manipulation of tau pre-mRNA to modify tau isoform expression.

Expert opinion: Several small molecule tau-based treatments are currently being assessed in clinical trials, the outcomes of which are eagerly awaited. Current evidence suggests that therapies targeting tau are likely, at least in part, to form the basis of an effective and safe treatment for Alzheimer's disease and related neurodegenerative disorders in which tau deposition is evident.

Keywords::

• aggregation
• Alzheimer's disease
• autophagy
• chaperone
• immunotherapy
• phosphorylation
• tau
• tauopathy
• therapeutic

Acknowledgement

The authors thank M Hutton of Eli Lilly and Co for his critical discussion of the manuscript.

Notes

This box summarises key points contained in the article.